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INTRODUCTION
Sentinel lymph node biopsy (SLNB) has become the standard 
method for axillary staging of breast cancer with reliable accu-
racy and fewer morbidities compared to complete axillary lymph 
node dissection (ALND) [1-3]. A sentinel lymph node (SLN) 
is defined as one of the first nodes to receive lymphatic drain-
age from a tumor bed [4,5]. However, there may be more than 
one SLN in an axillary bed [6,7], and the SLN is now defined 
as any lymph node or first set of nodes that receives direct lym-
phatic drainage from a primary tumor [8,9]. 
The mean number of SLNs removed ranges from 1.2 to 3.4, 
with the total number ranging from 1 to 8 [7,10-14]. Faced with 
multiple SLNs during the SLNB procedure, one of the primary 
issues is how many SLNs should be removed. This question 
needs to be answered, because the number of SLNs removed 
is significantly associated with an increased incidence of axil-
lary complications [15].
To date, the optimal number of SLNs that should be removed 
to accurately predict axillary lymph node status remains con-
troversial. We hypothesized that there might be an optimal 
threshold number of SLNs to be removed to achieve acceptable 
accuracy. The aim of this study was to determine the appropri-
ate number of SLNs to be removed for accurate axillary staging 
with minimal morbidity. 
METHODS
Between January 2004 and December 2005, 328 patients with 
clinically node negative invasive breast cancer, who underwent 
SLNB followed by complete levels I and II ANLD at Severance 
Hospital, Yonsei University College of Medicine in Seoul, Korea 
were enrolled. We excluded patients who had neoadjuvant 
chemotherapy, previous axillary surgery or radiation, and those 
who did not consent to scheduled surgical procedures. Patients 
who only underwent a SLNB or in whom we could not detect 
SLNs were also excluded. The information regarding SLN char-
acteristics (number and order of SLNs) and pathological find-
ings (SLNs and non-sentinel lymph nodes) were prospectively 
recorded in the Severance Hospital Breast Cancer Registry.  
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Purpose: During a sentinel lymph node biopsy (SLNB) for breast 
cancer, the appropriate number of sentinel lymph nodes (SLNs) 
to be removed for accurate axillary staging is still controversial. We 
hypothesized that there might be an optimal threshold number 
of SLNs. We investigated how many SLNs should be removed to 
achieve an acceptable accuracy and ensure minimal morbidity. 
Methods: We reviewed data of 328 patients with invasive breast 
cancer who underwent SLNB followed by complete level I and II 
axillary dissection between January 2004 and December 2005. 
The false negative rate (FNR) and accuracy of SLNB according 
to the number of removed SLNs were evaluated. Results: The 
mean number of SLNs removed was 3.0 (range, 1-14), and that 
of total retrieved axillary lymph nodes was 17.5 (range, 10-40). In 
total, 111 (33.8%) patients had positive nodes on the permanent 
pathological report. Among them, 12 patients had negative SLNs; 
thus, the overall FNR of SLNB was 10.8% (12/111) and the accu-
racy was 96.3% (316/328). The FNR was 26.6% for a single SLN, 
8.0% for two, and 11.1% for three. In cases where four or more 
SLNs were removed, the FNR decreased to 0% and accuracy 
reached 100%. Conclusion: Our data suggest that a SLNB should 
not only remove one or two of the hottest node(s) when other hot 
nodes exist. We also suggest that four might be an optimal thresh-
old number of SLNs to be removed and that removal of more than 
four SLNs does not improve axillary staging accuracy.
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SLN detection was only performed using the radio-isotope 
technique. On the day of surgery, 18.5 MBq (0.5 mCi) 99mTc 
Phytate (Korea Atomic Energy Research Institute, Daejeon, 
Korea) diluted in 0.5 mL saline was injected using the subare-
olar technique. A lymphoscintigraphy was performed after 
injection. The incision was made over the hottest area identified 
using a handheld probe (Navigator GPS; RMD Inc., Watertown, 
USA). After opening the axillary fascia, a handheld gamma 
probe was inserted to detect areas of concentrated hot nodes 
and to guide the ANLD. SLNs were judged as any node with 
radioactive counts 10% or more of the ex vivo count of the most 
radioactive SLN. After the SLNB, all patients received planned 
level I/II ANLD by two experienced breast surgeon regardless 
of SLN status to validate our early experience with SLNB. 
SLNs <1 cm were cut into two blocks, and two serial sections 
were taken from one block for the frozen sections, whereas 
another block was subsequently converted to paraffin sections. 
Intraoperatively frozen sections were stained with hematoxylin 
and eosin (H&E). The remaining frozen specimens and all non-
sentinel nodes underwent a routine pathological evaluation 
using H&E with or without immunohistochemical staining 
for cytokeratin. Patients with metastases detected by any method 
were considered positive for metastatic disease. Isolated tumor 
cells measuring <0.2 mm were classified as N0 disease. The 
false negative rate was defined as the proportion of patients 
with negative SLN findings on frozen or permanent sections 
who were subsequently found to have disease in the axillary 
lymph nodes on ALND. Accuracy is the proportion of all pa-
tients (positive or negative findings of sentinel lymph node 
biopsy) for whom the SNB correctly predicted the ALND 
results. The false negative rate (FNR) and accuracy of SLNB 
were evaluated according to the number of removed SLNs. 
RESULTS 
The patient clinicopathological characteristics are summa-
rized in Table 1. The mean age of the patients was 48.1 years 
(range, 24-79 years). In total, 216 (65.9%) patients underwent a 
total mastectomy, and 112 (34.1%) received breast conservation 
therapy. The primary tumor classification was 210 patients 
(64.0%) with T1 and 118 patients (36.0%) with T2. Invasive 
ductal carcinoma was the most common histological tumor 
type (323/328, 98.5%). There were four (1.2%) invasive lobu-
Table 1. Patients’ clinicopathologic characteristics (n=328)
Characteristic No. of patients (%)
Age (yr)*   48.1±9.6 (24-79)
T stage
   T1 210 (64.0)
   T2 118 (36.0)
N stage
   Negative 217 (66.2)
   Positive 111 (33.8)
Type of operation
   MRM 216 (65.9)
   BCT 112 (34.1)
Histology
   Invasive ductal carcinoma 323 (98.5)
   Invasive lobular carcinoma   4 (1.2)
   Other   1 (0.3)
No. of sampled SLN* 2.98±2.1 (1-14)
Total no. of retrieved ALN*   17.5±5.9 (10-40)
MRM=modified radical mastectomy; BCT=breast conserving therapy; SLN= 
sentinel lymph node; ALN=axillary lymph node.
*Mean±SD (range).
Table 2. False negative rate and accuracy according to the number of dissected SLNs
No. of dissected SLNs 
   (No. of patients)
True negative False negative True positive
False negative rate, % 
 (No. of patients)*
Accuracy, % 
 (No. of patients)†
     1 (92)   62   8 22 26.6 (8/30) 91.3 (84/92)
     2 (82)   57   2 23 8.0 (2/25) 97.6 (80/82)
     3 (57)   39   2 16 11.1 (2/18) 96.5 (55/57)
     4 (32)   18   0 14 0 (0/14) 100 (32/32)
     5 (28)   14   0 14 0 (0/14) 100 (28/28)
     6 (12)     6   0   6 0 (0/6) 100 (12/12)
     7 (12)     9   0   3 0 (0/3) 100 (12/12)
     8 (6)     5   0   1 0 (0/1) 100 (6/6)
     9 (2)     2   0   0 - (0/0) 100 (2/2)
   10 (1)     1   0   0 - (0/0) 100 (1/1)
≥11 (4)     4   0   0 - (0/0) 100 (4/4)
Total (328) 217 12 99 10.8 (12/111) 96.3 (316/328)
SLN=sentinel lymph node.
*The proportion of patients with negative SLN findings on frozen or permanent sections who were subsequently found to have disease in the axillary lymph nodes 
on axillary lymph node dissection (ALND); †All patients (positive or negative findings of sentinel lymph node biopsy) for whom the sentinel lymph node biopsy cor-
rectly predicted the ALND results.
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lar carcinomas and one (0.3%) other cancer. 
The number of SLNs identified at the time of surgery ranged 
from 1 to 14 (mean, 3.0±2.1). The mean number of retrieved 
axillary nodes examined was 17.5±5.9 (range, 10-40). Patho-
logically positive axillary lymph nodes were identified in 111 
(33.8%) patients (Table 1). Of patients with negative SLNs, 12 
patients had positive non-sentinel axillary lymph nodes yield-
ing a FNR of 10.8% (12/111) and the overall accuracy of SLNB 
in our series was 96.3% (316/328) (Table 2).
Clinicopathological characteristics of the 111 patients with 
positive axillary lymph nodes were compared with 12 cases of 
false negative patients and 99 cases of true positive using the 
chi-square test. No differences in age distribution, tumor size, 
estrogen receptor status, or histological grade were observed 
(data not shown). 
There were five cases of isolated tumor cells, pN0[i+], seven 
cases of pN1mi, and five cases of macrometastasis in which 
the frozen SLN sections were negative but permanent sections 
were positive. Therefore, 12 (3.7%) false negative cases were 
found during the freezing process, and these were not consid-
ered false negative results. 
The number of SLNs removed and the corresponding num-
ber of patients are summarized in Table 2. Ninety-two patients 
(28.0%) had one SLN removed, 82 patients (25.0%) had two 
SLNs removed, 57 patients (17.3%) had three SLNs removed, 
and 32 patients (9.7%) had four SLNs removed. More than four 
SLNs were removed in 65 patients (19.8%). The FNR was 26.6% 
(8/30) for single SLN removal, 8.0% (2/25) for two SLNs, and 
11.1% (2/18) for three. When four SLNs were removed, the 
FNR was 0% (0/14). The accuracy of SLNB was 91.3% (84/92) 
for single SLN removal, 97.6% (80/82) for two, and 96.5% (55/ 
57) for three. When four SLNs were removed, the accuracy was 
100%, and removing more than four SLNs did not improve the 
accuracy of axillary staging any further (Table 2). The FNR 
and accuracy according to the number of SLNs removed are 
summarized in Table 3. The overall pathological status of SLN 
and axillary lymph nodes are summarized in Table 4. The accu-
racy of SLNB was 100% with 0% FNR when four or more SLNs 
were removed. 
DISCUSSION
SLNB has replaced ALND as the stand-alone axillary stag-
ing procedure for patients with clinically node negative breast 
cancer. The NSABP B-32 trial, the largest multicenter trial to 
date for the evaluation of SLNB, confirmed that overall sur-
vival, disease-free survival, and regional control were equiva-
lent between an SLNB alone group and a SLNB with axillary 
dissection group [16].
A SLN is defined as the first node to receive lymphatic drain-
age from a primary tumor bed [4,5]; however, the actual expe-
rience of most investigators includes more than one SLN and 
controversy still exists regarding the optimal number of radio-
active SLNs that should be removed to ensure accuracy and 
minimize morbidity [6,7]. 
One of the possible explanations for identifying multiple 
SLNs is the “pass-through” phenomenon, which reflects iso-
tope migration from the ‘‘true’’ SLN into secondary echelon 
lymph nodes. Another simple explanation is normal anatomi-
cal variation in which the lymphatics of a given site simultane-
ously drain into more than one SLN [7].
A benefit of SLNB is that it removes fewer nodes compared 
with standard ALND, thereby reducing morbidity. The key 
factor used to assess the success of SLNB is the FNR because 
it defines the frequency of negative SLNs when other axillary 
nodes have metastases. So, an acceptable accuracy of axillary 
Table 3. False negative rate according to the number of dissected SLNs, cumulative
No. of dissected SLNs 
   (No. of patients)
True negative False negative True positive
False negative rate, % 
(No. of patients)*
Accuracy, % 
(No. of patients)†
1 or more (328) 217 12 99   10.8 (12/111)    96.3 (316/328)
2 or more (236) 155   4 77 5.0 (4/81)    98.3 (232/236)
3 or more (154)   98   2 54 3.5 (2/56)    98.7 (152/154)
4 or more (97)   59   0 38    0 (0/38) 100 (97/97)
SLN=sentinel lymph node.
*The proportion of patients with negative SLN findings on frozen or permanent sections who were subsequently found to have disease in the axillary lymph nodes 
on axillary lymph node dissection (ALND); †All patients (positive or negative findings of sentinel lymph node biopsy) for whom the sentinel lymph node biopsy cor-
rectly predicted the ALND results.
Table 4. Overall pathologic status of SLN and total retrieved ALN in T1-2 
breast cancer patients
SLN status
Total retrieved ALN status
Total
Negative Positive
Negative 217   12 229
Positive     0   99   99
Total 217 111 328
False negative rate is 10.8% (12/111), and overall accuracy is 96.3% (316/328).
SLN=sentinel lymph node; ALN=axillary lymph node.
Appropriate Number of Sentinel Lymph Node Biopsy 299
http://dx.doi.org/10.4048/jbc.2011.14.4.296 http://ejbc.kr
staging must be determined to minimize SLNB-related mor-
bidity. 
How many sentinel nodes should be removed to achieve 
appropriate accuracy of axillary staging without negating the 
potential benefits of SLNB? We hypothesized that there is a 
point when the surgeon can terminate the procedure without 
sacrificing SLNB accuracy. In our series, 100% of positive SLNs 
were identified in one of the first three lymph nodes removed 
in patients with node positive disease. Furthermore, 100% accu-
racy of SLNB was achieved by excising four nodes but removing 
all SLNs with radioactive counts >10% of the ex vivo counts 
of the hottest SLN did not increase accuracy. 
Our data are quite comparable to the majority of published 
series that have evaluated the optimal number of SLNs and 
support the trend of limiting SLN biopsy to 3-4 lymph nodes. 
Although no clear data exist regarding limiting axillary dissec-
tion based on relative radioactive counts, limiting SLNB to a 
reasonable number of nodes, about 3 or 4, is well supported by 
several case series, including this report. Published data show 
that 97-98% of positive SLNs are discovered in one of the first 
three nodes examined, and that it is rare to find a positive SLN 
after identifying the first three nodes as negative [6,7,14,17-20]. 
Some recent data also demonstrate that >98% of positive SLNs 
are identified in one of the first four lymph nodes removed [21]. 
These data demonstrate that the total number of SLNs to be 
excised can be limited to four without jeopardizing the accu-
racy of axillary staging. We suggest that the SLN should be 
among the hot nodes if all hot nodes are removed, but not all 
hot nodes are SLNs. 
In 2001, McCarter et al. [7], suggested that there is no abso-
lute upper threshold for the number of SLNs that should be 
removed. However, indiscriminate removal of axillary nodes 
may not be justified, considering operative complications and 
resource utilization associated with SLNB. Data from the 
ACOSOG Z0010 prospective trial comparing SLNB only with 
SLNB followed by complete ALND found an increase in the 
rate of axillary seroma formation and wound infections in pa-
tients who had more than four SLNs removed [15]. Further-
more, cost-effectiveness and cost utilization studies have found 
that excising a high number of SLNs is associated with longer 
operation time, higher pathology costs, and higher procedural 
costs [22]. Terminating the procedure after the fourth node 
may lower the cost of the procedure and reduce morbidity. 
Our data also suggest that removing only a single SLN in-
creased the risk for FNR. In our series, FNR was 26.6% for a 
single SLN removed, which is outside the acceptable FNR range 
of 5-10% [23-25]. It has been established that the SLN with the 
highest radioactive counts is not always the SLN that is most 
likely to harbor metastatic disease [26,27]. Why is an SLN not 
necessarily the “hottest” node in the lymphatic basin? We can 
offer three reasons for this. First, when the radioactive tracer 
passes through an SLN, if the next lymph node stage is relatively 
large or if there are active phagocytic cells, more radioactivity 
material is accumulated than in the first lymph node stage. 
Second, the amount of radioactive tracer accumulated in a 
lymph node not only depends on the order of drainage but 
also reflects the number of lymphatic channels and lymphatic 
flow. Last, if a true SLN is occupied by metastatic cells, it can-
not absorb radioactive tracer. In that case, another lymph node 
will ingest tracer and be recognized as an SLN. Therefore, we 
cannot say that the so-called “hottest node,” which absorbs the 
most radioactive tracer, is always the first SLN [28,29]. In this 
respect, to find the SLNs in a case of fewer than four hot nodes 
should be a very important line of research in the near future.
Limitation of the present study was a different proportion 
of operation methods compared to the nationwide Korean 
Breast Cancer Society (KBCS) registration program. Ko and 
the KBCS [30] reported that approximately 50-55% of whole 
breast cancer patients including in situ carcinoma and meta-
static disease underwent total mastectomy during same study 
period. Since type of surgery is determined not only by tumor 
size but also by various clinicopathological parameters, radio-
logical findings, or a patient’s desire, our present results using 
selected study cohort at single institution remain to validated 
in an independent dataset.
In conclusion, excising all SLNs with >10% of the counts of 
the hottest SLN could result in oversampling. We suggest that 
the total number of SLNs excised be limited to no more than 
four. We also suggest that the SLNB is not complete by remov-
ing only one or two nodes or only the hottest node. By remov-
ing only the nodes most likely to contain metastases, the SLN 
procedure potentially avoids complications commonly described 
for ALND without compromising staging.
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